Pfizer Inc
Close on Oct 30, 2026Market cap $173.95BP/E 40.2Yield 5.64%
Pfizer Zirabev [legacy through FY23] by Year
Zirabev (bevacizumab biosimilar) [legacy through FY23] — U.S. reported YoY (%) (%)
Pfizer Zirabev [legacy through FY23]: -30.0% in FY2023, down 31.0 pts from a year earlier. No newer figure appears in the documents we track.
Where the FY2023 figure comes from
“|| Zirabev | 75 | 100 | (25%) | (26%) | 27 | 38 | (30%) | (25%) | 18 | 11 | 64% | 89%”
Source: Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗
Reported in Form 8-K Revenue Tables.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Zirabev (bevacizumab biosimilar) [legacy through FY23] — U.S. reported YoY (%) (%) | Year on year | Source |
|---|---|---|---|---|
| FY2023 | Dec 31, 2023 | -30.0% | -31.0 pts | Form 8-K (Earnings / Guidance Release) (pfe-12312023xex99.htm, filed 2024-01-30) ↗ |
| FY2022 | Dec 31, 2022 | 1.0% | – | Form 8-K (Earnings / Guidance Release) (pfe-12312022xex99.htm, filed 2023-01-31) ↗ |
Cite this data
StockData. (2026). Pfizer Zirabev [legacy through FY23] (%), annual FY2022–FY2023 [Data set]. Compiled from Pfizer SEC filings and investor materials. https://stockdatahq.com/stocks/pfe/kpis/zirabev-leg-yoy-us
See every metric in the Pfizer KPI table. Data updated Nov 2, 2026.